New hope for elderly lymphoma patients: a gentler treatment that preserves independence

NCT ID NCT04113226

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This phase 2 trial investigates whether combining rituximab with lenalidomide works as well as standard rituximab-based chemotherapy for patients aged 75 and older with relapsed diffuse large B-cell lymphoma. The study focuses not only on controlling the cancer but also on maintaining the patients' ability to perform daily activities independently. Participants receive either the lenalidomide combination or standard chemotherapy, with the goal of finding a treatment that balances effectiveness with quality of life.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
Rituximab and Lenalidomide
What this could lead to
If successful, this could offer a gentler, effective treatment option for elderly patients with relapsed DLBCL, helping them live longer while maintaining independence.
What could go wrong
This is a small, early-phase trial, so results may not apply broadly. Lenalidomide can cause side effects like low blood counts, fatigue, or blood clots.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHEMOTHERAPY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • CHU Amiens

    Amiens, 80054, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.